Very long-term complete remission can be achieved in men with high-risk localized prostate cancer and a very high PSA value: an analysis of the GETUG 12 Phase 3 trial

[1]  C. Parker,et al.  Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Parmar,et al.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.

[3]  W. Oyen,et al.  Consensus on molecular imaging and theranostics in prostate cancer. , 2018, The Lancet. Oncology.

[4]  A. Ravaud,et al.  Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  N. Lenzo,et al.  The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer , 2017, Nuclear medicine communications.

[6]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[7]  R. Berger,et al.  Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation? , 2017, Radiation oncology.

[8]  S. Fosså,et al.  Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. , 2016, European urology.

[9]  K. Moretti,et al.  Men presenting with prostate‐specific antigen (PSA) values of over 100 ng/mL , 2016, BJU international.

[10]  A. Ravaud,et al.  Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. , 2015, The Lancet. Oncology.

[11]  Matthew R. Sydes,et al.  Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Chiung-Kuei Huang,et al.  Outcomes and predictive factors of prostate cancer patients with extremely high prostate-specific antigen level , 2014, Journal of Cancer Research and Clinical Oncology.

[13]  K. Kairemo,et al.  Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer , 2014, Nuclear medicine communications.

[14]  Tong Zhu,et al.  Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen. , 2012, International journal of radiation oncology, biology, physics.

[15]  B. Tombal,et al.  Is there a prostate‐specific antigen upper limit for radical prostatectomy? , 2011, BJU international.

[16]  D. Grignon,et al.  Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. , 2011, International journal of radiation oncology, biology, physics.

[17]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Leibovich,et al.  Long‐term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate‐specific antigen level ≥50 ng/mL , 2008, Cancer.

[19]  L. Collette,et al.  Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). , 2008, European urology.

[20]  Douglas G Altman,et al.  Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.

[21]  Jung‐Ta Chen,et al.  Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml. , 2003, Japanese journal of clinical oncology.

[22]  L. Holmberg,et al.  Prostate-specific Antigen as Surrogate for Characterizing Prostate Cancer Subgroups , 2002, Scandinavian journal of urology and nephrology.

[23]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[24]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[25]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[26]  Z. Ying,et al.  Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .

[27]  F. Harrell,et al.  Regression models in clinical studies: determining relationships between predictors and response. , 1988, Journal of the National Cancer Institute.

[28]  H. Akaike.  A new look at the statistical model identification , 1974 .

[29]  K. Izumi,et al.  Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL , 2019, International braz j urol : official journal of the Brazilian Society of Urology.

[30]  A. Ravaud,et al.  A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial. , 2012, European journal of cancer.

[31]  D.,et al.  Regression Models and Life-Tables , 2022 .